The Addition of a Nonsteroidal Anti-inflammatory Drug in Local Infiltration Analgesia During Total Knee Arthroplasty Increases the Risk of Acute Kidney Injury in Patients Who Have Renal Impairment: A Propensity-Matched Retrospective Cohort Study.

BACKGROUND

Local infiltration analgesia (LIA) is a crucial component of pain management during total knee arthroplasty (TKA), Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly included in the drug cocktail. The use of NSAIDs are associated with adverse renal, gastrointestinal, and cardiovascular effects. This study aimed to investigate whether the addition of an NSAID in LIA affects the incidence of acute kidney injury (AKI) in TKA patients, especially those who have pre-existing renal impairment. The secondary aim was to determine overall AKI incidence.

METHODS

A retrospective cohort study was conducted on elective, primary TKA patients in a single tertiary institution between January 2020 and April 2024. Patients were administered LIA intraoperatively, with or without an NSAID (30 mg of ketorolac). Patients who did or did not have chronic kidney disease (CKD) were analyzed separately. Propensity matching was performed on the CKD group, correcting for age, sex, body mass index, American Society of Anesthesiologists score, and presence of diabetes mellitus/hypertension. The outcome of interest was the incidence of AKI. We used t-tests or Chi-square tests to determine the statistical significance of the results.

RESULTS

In patients who had CKD (n = 114), the presence of ketorolac in LIA was associated with a higher AKI incidence (12.7 versus 2.0%, P = 0.041). In patients who did not have CKD (n = 870), the presence of ketorolac in LIA was not associated with a higher AKI incidence (2.0 versus 1.9%, P = 1.0). Overall AKI incidence was 2.6%.

CONCLUSIONS

In patients who have CKD, orthopaedic surgeons should be highly cautious of administering ketorolac in LIA during TKA, as it is associated with a higher risk of AKI. Patients who have normal renal function can be safely given ketorolac in LIA without an elevated risk of AKI. Further studies are needed to examine AKI incidence when other NSAIDs are used in LIA.